Aygen Bilgehan, Demir Ahmet Muzaffer, Gümüş Mahmut, Karabay Oğuz, Kaymakoğlu Sabahattin, Köksal Aydın Şeref, Köksal İftihar, Örmeci Necati, Tabak Fehmi
Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey.
Division of Hematology, Department of Internal Diseases, Trakya University School of Medicine, Edirne, Turkey.
Turk J Gastroenterol. 2018 May;29(3):259-269. doi: 10.5152/tjg.2018.18263.
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
本共识报告包含了有关筛查以及必要时对因乙型肝炎再激活紧急风险而将接受免疫抑制治疗的患者在治疗前进行乙型肝炎随访、预防和治疗的专家意见与建议。为提高对免疫抑制患者中乙型肝炎再激活风险的认识，来自土耳其多个大学健康研究与培训中心的院士齐聚一堂，根据当前文献数据讨论了该主题的重要性、现状及问题，并提出了解决方案。
